Research programme: granulocyte colony-stimulating factor - SkyePharmaAlternative Names: GCSF-SkyePharma; Granulocyte colony-stimulating factor - SkyePharma
Latest Information Update: 20 Oct 2005
At a glance
- Originator SkyePharma PLC
- Mechanism of Action Granulocyte colony stimulating factor stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Neutropenia
Most Recent Events
- 20 Oct 2005 Preclinical trials in Neutropenia in United Kingdom (unspecified route)